On Friday 05/23/2025 the closing price of the TG Therapeutics Inc share was $34.24 on BTT.
Compared to the opening price on Friday 05/23/2025 on BTT of $33.89, this is a gain of 1.02%.
TG Therapeutics Inc's market capitalization is $4.52 B by 158.76 M shares outstanding.
Is TG Therapeutics stock a Buy, Sell or Hold?
TG Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 11 buy ratings, 4 hold ratings, and 1 sell ratings.What was the 52-week low for TG Therapeutics stock?
The low in the last 52 weeks of TG Therapeutics stock was 15.17. According to the current price, TG Therapeutics is 227.62% away from the 52-week low.What was the 52-week high for TG Therapeutics stock?
The high in the last 52 weeks of TG Therapeutics stock was 46.48. According to the current price, TG Therapeutics is 74.29% away from the 52-week high.What are analysts forecasts for TG Therapeutics stock?
The 16 analysts offering price forecasts for TG Therapeutics have a median target of 34.06, with a high estimate of 55.00 and a low estimate of 12.00. The median estimate represents a 101.37 difference from the last price of 34.53.TG Therapeutics Stock Snapshot
34.57
Bid
9.00
Bid Size
38.95
Ask
100.00
Ask Size
5/23/2025
Date
3:59 PM
Time
36,900.00
Volume
34.24
Prev. Close
33.89
Open
5.49 B
Market Cap in USD
158.76 M
Number of Shares
158.76 M
Total Number of Shares
33.58
Day Low
34.64
Day High
34.53
15.17
52 Week Low
46.48
52 Week High
34.53
0.00
Dividend in USD
0.00
Dividend Yield
206.45
P/E Ratio
90.04
Free Float in %
0.15
EPS in USD
1.43
Book Value per Share in USD
-0.25
Cash Flow per Share in USD
TG Therapeutics News More News
Historical Prices for TG Therapeutics
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
TG Therapeutics Analyst Data
Total Analysts: 16
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 12.00
Median: 34.06
Highest: 55.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
TG Therapeutics Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 03/04/25 | H.C. Wainwright & Co. | Maintained Buy | $55 | |||
| 05/02/24 | H.C. Wainwright & Co. | Maintained Buy | $49 | |||
| 05/02/24 | Ladenburg Thalmann & Co. Inc. | Maintained Buy | $40 | |||
| 04/18/24 | H.C. Wainwright & Co. | Maintained Buy | $45 | |||
| 04/18/24 | J.P. Morgan | Maintained Buy | $25 | |||
| 04/18/24 | Ladenburg Thalmann & Co. Inc. | Maintained Buy | $39 | |||
| 02/29/24 | Goldman Sachs | Maintained Hold | $13 | |||
| 02/28/24 | H.C. Wainwright & Co. | Maintained Buy | $45 | |||
| 01/11/24 | H.C. Wainwright & Co. | Maintained Buy | $45 | |||
| 11/01/23 | J.P. Morgan | Maintained Buy | $23 | |||
| 09/18/23 | H.C. Wainwright & Co. | Maintained Buy | $41 | |||
| 08/07/23 | J.P. Morgan | Maintained Buy | $22 | |||
| 08/02/23 | Goldman Sachs | Upgraded to Hold | $12 | |||
| 08/01/23 | H.C. Wainwright & Co. | Maintained Buy | $41 | |||
| 07/24/23 | Goldman Sachs | Maintained Sell | $16 | |||
| 05/31/23 | H.C. Wainwright & Co. | Maintained Buy | $34 |
TG Therapeutics Estimates* in USD
| 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|
| Revenue | 581 | 808 | 1,012 | 1,407 | 1,640 |
| Dividend | 0.00 | 0.00 | - | - | - |
| Dividend Yield (in %) | 0.00 % | 0.00 % | - | - | - |
| EPS | 0.89 | 1.78 | 2.46 | 3.74 | 4.62 |
| P/E Ratio | 38.84 | 19.39 | 14.06 | 9.26 | 7.49 |
| EBIT | 166 | 318 | 463 | 843 | 1,048 |
| EBITDA | 181 | 305 | 320 | - | - |
| Net Profit | 145 | 290 | 399 | 594 | 775 |
| Net Profit Adjusted | 169 | 311 | 415 | 603 | 751 |
| Pre-Tax Profit | 153 | 311 | 460 | 748 | 1,035 |
| Pre-Tax Profit Reported | 119 | 198 | 325 | - | - |
| EPS (Non-GAAP) ex. SOE | 1.03 | 1.96 | 2.50 | - | - |
| EPS (GAAP) | 0.89 | 1.78 | 2.46 | 3.74 | 4.62 |
| Gross Income | 515 | 712 | 930 | 1,256 | 1,464 |
| Cash Flow from Investing | 60 | -9 | -15 | -52 | -83 |
| Cash Flow from Operations | 207 | 288 | 421 | 743 | 892 |
| Cash Flow from Financing | -199 | -54 | -54 | 0 | 0 |
| Cash Flow per Share | 0.30 | 1.85 | 1.76 | - | - |
| Free Cash Flow | 183 | 205 | 294 | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | 0.80 | 2.33 | 4.11 | - | - |
| Net Debt | 64 | -134 | -343 | - | - |
| Research & Development Exp. | 142 | 157 | 176 | 199 | 175 |
| Capital Expenditure | 5 | 9 | 15 | 52 | 83 |
| Selling, General & Admin. Exp. | 207 | 226 | 220 | 231 | 240 |
| Shareholder’s Equity | 127 | 378 | 668 | - | - |
| Total Assets | 427 | 588 | 866 | - | - |
|
Previous Quarter ending 03/31/25 |
Current Quarter ending 06/30/25 |
Next Quarter ending 09/30/25 |
Current Year ending 12/31/25 |
Next Year ending 12/31/26 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 6 | 7 | 7 | 7 |
| Average Estimate | - | 0.197 USD | 0.247 USD | 0.890 USD | 1.783 USD |
| Year Ago | - | 0.048 USD | 0.027 USD | 0.161 USD | - |
| Publish Date | - | 8/5/2025 | 10/30/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 6 | 7 | 6 | 7 |
| Average Estimate | - | 137 USD | 151 USD | 581 USD | 808 USD |
| Year Ago | - | 73 USD | 84 USD | 329 USD | - |
| Publish Date | - | 8/5/2025 | 10/30/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales | 329.00 | 233.66 | 2.79 | 6.69 | 0.15 | 0.15 | 0.15 |
| Change of sales in % | 40.80 | 8,290.02 | -58.36 | 4,300.66 | 0.00 | 0.00 | -0.25 |
| Gross profit on sales | 290.24 | 219.11 | 2.01 | 5.90 | -0.22 | -0.13 | 0.06 |
| Gross profit on sales change in % | 32.46 | 10,828.08 | -66.01 | - | -70.77 | - | -8.61 |
| Operating income | 41.93 | 20.63 | -192.84 | -344.77 | -273.59 | -170.26 | -174.40 |
| Operating income change in % | 103.21 | - | 44.07 | -26.02 | -60.70 | 2.38 | -46.91 |
| Income before tax | 25.59 | 13.06 | -198.34 | -348.10 | -279.38 | -172.87 | -173.48 |
| Income before tax change in % | 95.94 | - | 43.02 | -24.60 | -61.61 | 0.35 | -46.43 |
| Income after tax | 23.38 | 12.67 | -198.34 | -348.10 | -279.38 | -172.87 | -173.48 |
| Income after tax change in % | 84.52 | - | 43.02 | -24.60 | -61.61 | 0.35 | -46.43 |
Balance Sheet in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 355.33 | 169.09 | 134.99 | 142.48 | 106.29 | 124.40 | 59.58 |
| Long-term liabilities per share | 1.70 | 0.76 | 0.56 | 0.54 | 0.13 | 0.37 | 0.25 |
| Equity | 222.36 | 160.50 | 58.59 | 237.15 | 519.35 | 38.62 | 24.04 |
| Equity change in % | 38.54 | 173.95 | -75.30 | -54.34 | 1,244.94 | 60.65 | -64.12 |
| Balance sheet total | 577.69 | 329.59 | 193.57 | 379.63 | 625.64 | 163.01 | 83.62 |
| Balance sheet total change in % | 75.28 | 70.27 | -49.01 | -39.32 | 283.80 | 94.96 | -14.14 |
Key Data in USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 2.05 | 1.57 | 0.02 | 0.05 | 0.00 | 0.00 | 0.00 |
| P/E ratio (year end quote, basic EPS) | 206.45 | 200.23 | - | - | - | - | - |
| P/E ratio (year end quote, diluted EPS) | 206.45 | 200.23 | - | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 38.49 | 48.70 | 30.27 | 62.47 | 83.01 | 23.69 | 28.75 |
| Debt ratio in % | 61.51 | 51.30 | 69.73 | 37.53 | 16.99 | 76.31 | 71.25 |
TG Therapeutics Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Charney Laurence N | 03/09/2025 | 6,000.00 | 201,479.00 | n/a | Sell | No |
| Power Sean A | 01/28/2025 | 87,500.00 | 708,111.00 | n/a | Buy | No |
| WEISS MICHAEL S | 01/28/2025 | 750,000.00 | 13,824,929.00 | n/a | Buy | No |
| Power Sean A | 01/05/2025 | 10,021.00 | 660,611.00 | 28.53 | Sell | No |
| Power Sean A | 01/02/2025 | 11,337.00 | 670,632.00 | 30.29 | Sell | No |
| Charney Laurence N | 11/11/2024 | 5,000.00 | 207,479.00 | n/a | Sell | No |
| Charney Laurence N | 11/10/2024 | 25,000.00 | 212,479.00 | 30.20 | Sell | No |
| Lonial Sagar | 11/10/2024 | 5,000.00 | 100,195.00 | 30.44 | Sell | No |
| Echelard Yann | 11/04/2024 | 20,000.00 | 224,098.00 | 24.48 | Sell | No |
| Lonial Sagar | 06/19/2024 | 16,348.00 | 105,195.00 | 16.87 | Sell | No |
| Charney Laurence N | 06/18/2024 | 22,250.00 | 237,479.00 | n/a | Buy | No |
| HUME DANIEL | 06/18/2024 | 22,250.00 | 240,489.00 | n/a | Buy | No |
| Lonial Sagar | 06/18/2024 | 22,250.00 | 121,543.00 | n/a | Buy | No |
| Hoberman Kenneth | 06/18/2024 | 22,250.00 | 264,935.00 | n/a | Buy | No |
| Echelard Yann | 06/18/2024 | 22,250.00 | 244,098.00 | n/a | Buy | No |
| Lonial Sagar | 06/16/2024 | 9,585.00 | 99,293.00 | 16.39 | Sell | No |
| Lonial Sagar | 03/12/2024 | 5,000.00 | 108,878.00 | 15.94 | Sell | No |
| Charney Laurence N | 03/11/2024 | 22,000.00 | 215,229.00 | 15.97 | Sell | No |
| WEISS MICHAEL S | 01/05/2024 | 1,001,908.00 | 13,074,929.00 | n/a | Buy | No |
| Charney Laurence N | 01/04/2024 | 17,500.00 | 237,229.00 | 19.03 | Sell | No |
| Power Sean A | 01/04/2024 | 75,000.00 | 681,969.00 | n/a | Buy | No |
| Power Sean A | 01/02/2024 | 47,867.00 | 606,969.00 | 16.91 | Sell | No |
| Lonial Sagar | 09/27/2023 | 20,000.00 | 113,878.00 | n/a | Sell | No |
| Echelard Yann | 09/27/2023 | 20,000.00 | 221,848.00 | n/a | Buy | No |
| Hoberman Kenneth | 09/27/2023 | 20,000.00 | 242,685.00 | n/a | Buy | No |
TG Therapeutics Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2024 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2023 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2022 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2021 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2020 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2019 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2018 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2017 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2016 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2015 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2014 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2013 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2012 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2011 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2010 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
| 2009 | TG Therapeutics Inc | 0.00 | 0.00 | USD |
*Yield of the Respective Date
TG Therapeutics Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Annual General Meeting | 0.150 USD | Annual General Meeting | 06/12/2025 |
| Earnings Report | 0.197 USD | Q2 2025 Earnings Release | 08/05/2025 |
| Earnings Report | 0.247 USD | Q3 2025 Earnings Release | 10/30/2025 |
| Earnings Report | 0.307 USD | Q4 2025 Earnings Release | 03/03/2026 |
| Earnings Report | 0.365 USD | Q1 2026 Earnings Release | 05/11/2026 |
TG Therapeutics Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 0.030 USD | Q1 2025 Earnings Release | 05/05/2025 |
| Earnings Report | 0.150 USD | Q4 2024 Earnings Release | 03/03/2025 |
| Earnings Report | 0.020 USD | Q3 2024 Earnings Release | 11/04/2024 |
| Earnings Report | 0.040 USD | Q2 2024 Earnings Release | 08/06/2024 |
| Annual General Meeting | 0.090 USD | Annual General Meeting | 06/14/2024 |
| Earnings Report | -0.070 USD | Q1 2024 Earnings Release | 05/01/2024 |
| Earnings Report | -0.090 USD | Q4 2023 Earnings Release | 02/28/2024 |
| Earnings Report | 0.730 USD | Q3 2023 Earnings Release | 11/01/2023 |
| Earnings Report | -0.340 USD | Q2 2023 Earnings Release | 08/01/2023 |
| Annual General Meeting | -1.460 USD | Annual General Meeting | 06/14/2023 |
| Earnings Report | -0.280 USD | Q1 2023 Earnings Release | 05/01/2023 |
| Earnings Report | -0.390 USD | Q4 2022 Earnings Release | 02/28/2023 |
| Earnings Report | -0.260 USD | Q3 2022 Earnings Release | 11/10/2022 |
| Earnings Report | -0.300 USD | Q2 2022 Earnings Release | 08/08/2022 |
| Annual General Meeting | -2.630 USD | Annual General Meeting | 06/16/2022 |
| Earnings Report | -0.510 USD | Q1 2022 Earnings Release | 05/11/2022 |
| Earnings Report | -0.700 USD | Q4 2021 Earnings Release | 03/01/2022 |
TG Therapeutics Profile
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.